Navigation Links
New steps toward a universal flu vaccine
Date:5/19/2010

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their findings today in the inaugural issue of mBio, the first online, open-access journal published by the American Society for Microbiology.

"Current influenza vaccines are effective against only a narrow range of influenza virus strains. It is for this reason that new vaccines must be generated and administered each year. We now report progress toward the goal of an influenza virus vaccine which would protect against multiple strains," says Peter Palese, an author on the study.

The main reason the current seasonal vaccine is so strain-specific is that the antibodies it induces are targeted at the globular head of the hemaglutinin (HA) molecule on the surface of the influenza virus. This globular head is highly variable and constantly changing from strain to strain.

In this study the researchers constructed a vaccine using HA without its globular head. Mice immunized with the headless HA vaccine showed a broader, more robust immune response than mice immunized with full-length HA, and that immune response was enough to protect them against a lethal viral challenge.

"Our results suggest that the response induced by headless HA vaccines is sufficiently potent to warrant their further development toward a universal influenza virus vaccine. Through further development and testing, we predict that a single immunization with a headless HA vaccine will offer effective protection through several influenza epidemics," says Palese.

In a related article, also appearing in the inaugural issue of mBio, Antonio Cassone of the Instituto Superiore di Sanit, Rome, Italy, and Rino Rappuoli of Novartis Vaccines and Diagnostics, Siena, Italy, comment on the research and movement in the future towards universal vaccines.

"Recent research demonstrating the possibility of protecting against all influenza A virus types or even phylogenetically distant pathogens with vaccines based on highly conserved peptide or saccharide sequences is changing our paradigm," they write. "Is influenza the only disease that warrants approaches for universal vaccines? Clearly it is not."

They go on to note that a universal pneumococcal vaccine is already being discussed, as well as one for HIV. Universal vaccine strategies could also be used to protect against antibiotic-resistant bacteria and fungi for which no vaccine is currently available.

"There is now hope, sustained by knowledge and technology, for the generation of broadly protective universal vaccines restricted to species or groups of closely related pathogens," they write.


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. Structure of 450 million year old protein reveals evolutions steps
2. Researchers take first steps towards spinal cord reconstruction following injury
3. Researchers move 2 steps closer to understanding genetic underpinnings of autism
4. Steps toward Stopping Autoimmune Disease
5. Research uncovers new steps on pathway to enlarged heart
6. Cystic fibrosis testing -- next steps
7. Metastatic bone disease patients can walk in Lazarus footsteps
8. Trans fats hinder multiple steps in blood flow regulation pathways
9. Report shows the power of US cities to mitigate climate change and steps they need to take to adapt
10. Scientists take early steps toward mapping epigenetic variability
11. Consumers over age 50 should consider steps to cut copper and iron intake
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology: